CN108478604A - A kind of salmonella inhibitor - Google Patents
A kind of salmonella inhibitor Download PDFInfo
- Publication number
- CN108478604A CN108478604A CN201810400614.7A CN201810400614A CN108478604A CN 108478604 A CN108478604 A CN 108478604A CN 201810400614 A CN201810400614 A CN 201810400614A CN 108478604 A CN108478604 A CN 108478604A
- Authority
- CN
- China
- Prior art keywords
- salmonella
- lactobacillus plantarum
- inhibitor
- oligosaccharide
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000607142 Salmonella Species 0.000 title claims abstract description 51
- 239000003112 inhibitor Substances 0.000 title claims abstract description 32
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 81
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 81
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 80
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical group OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 25
- 229920001542 oligosaccharide Polymers 0.000 claims description 20
- 150000002482 oligosaccharides Chemical class 0.000 claims description 20
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 230000002147 killing effect Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 230000000968 intestinal effect Effects 0.000 abstract description 3
- 206010039438 Salmonella Infections Diseases 0.000 description 22
- 206010039447 salmonellosis Diseases 0.000 description 22
- 239000001963 growth medium Substances 0.000 description 16
- 229920001202 Inulin Polymers 0.000 description 14
- 229940029339 inulin Drugs 0.000 description 14
- 238000003304 gavage Methods 0.000 description 13
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 13
- 241001607429 Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 Species 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 229960000511 lactulose Drugs 0.000 description 10
- 230000012010 growth Effects 0.000 description 9
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 6
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 4
- GUBGYTABKSRVRQ-UHFFFAOYSA-N D-Cellobiose Natural products OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 241001462463 Lactobacillus plantarum ST-III Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- -1 citric acid Hydrogen Chemical class 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 235000021393 food security Nutrition 0.000 description 1
- 244000078673 foodborn pathogen Species 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of salmonella inhibitor, belong to biomedicine technical field.This inhibitor includes lactobacillus plantarum (Lactobacillus plantarum) ZS2058, can either avoid killing commensal gut flora largely beneficial to human body, occur into the side effect unfavorable to human body such as function of intestinal canal disorder；Salmonella can be avoided to generate resistance again, cause disruption of ecological balance；And, the advantage of no hysteresis quality good with inhibition.
Description
Technical field
The present invention relates to a kind of salmonella inhibitor, belong to biomedicine technical field.
Background technology
Salmonella (Salmonella) belongs to enterobacteriaceae, is a kind of global infecting both domestic animals and human pathogen and one
The important food-borne pathogens of kind, the incubation period after salmonella infection are generally 12 to 36 hours, the Salmonella being induced by it
Bacterium disease (salmonellosis), clinical manifestation are abdominal cramps, diarrhea, fever, vomiting, gastroenteritis etc., can even be drawn when serious
Situations such as playing septicemia or lethal newborn.
Its communication media is extensive, and food-borne route of infection includes by salmonella-polluted water, fresh or processing meat
Class, dairy products, eggs, shellfish, vegetables etc., the number that developing country infects salmonella every year are about 20,000,000, American-European flourishing
The crowd of country is similarly subjected to the puzzlement of salmonella, and only the number of the U.S. touching salmonella every year is just up to 1,400,000.
Salmonella causes the huge economic loss in countries in the world, seriously threatens people's health, therefore controls salmonella
Infection to ensureing that food security and mankind's public health security have great significance.
It is applied to the drug for the treatment of salmonella infection at present based on antibiotic, but using can also be killed while antibiotic
The extremely a large amount of commensal gut flora beneficial to human body, occurs into the side effect unfavorable to human body such as function of intestinal canal disorder；In addition, long
Phase causes salmonella to generate resistance to common antibiotic using antibiotic, the appearance of multi-drug resistant salmonella at
For universal phenomenon.And antibiotic is excessive using the antibiotic content in environment can also increased, and causes disruption of ecological balance；In part
Medicine composition can alleviate metainfective symptom, but effect is undesirable, and identical with antibiosis extract for treating both is to have hysteresis quality
Disadvantage.
Therefore, be badly in need of finding it is a kind of can either avoid killing the largely commensal gut flora beneficial to human body, occur into intestines
The side effect unfavorable to human body such as road dysfunction；Salmonella can be avoided to generate resistance again, cause disruption of ecological balance；And inhibit
It works well, the salmonella inhibitor of no hysteresis quality.
Invention content
To solve the above problems, the present invention provides a kind of salmonella inhibitor.This inhibitor includes lactobacillus plantarum
(Lactobacillus plantarum) ZS2058 can either avoid killing commensal gut flora largely beneficial to human body,
There is into the side effect unfavorable to human body such as function of intestinal canal disorder；Salmonella can be avoided to generate resistance again, cause ecological mistake
Weighing apparatus；And, the advantage of no hysteresis quality good with inhibition.
Technical scheme is as follows：
The present invention provides a kind of salmonella inhibitor, the ingredient of the inhibitor include lactobacillus plantarum and/or its
Metabolin；The lactobacillus plantarum is lactobacillus plantarum (Lactobacillus plantarum) ZS2058；The plant breast bar
Bacterium (Lactobacillus plantarum) ZS2058 is preserved on April 10th, 2006 in China typical culture collection
Heart preservation, deposit number are CCTCC No.M206033, and preservation address is wuchang, wuhan road gal mountain.The lactobacillus plantarum is
Lactobacillus plantarum (Lactobacillus plantarum) ZS2058 is disclosed in the special of Publication No. in the date (publication date)
In profit.
In one embodiment of the invention, the lactobacillus plantarum (Lactobacillus plantarum)
The content of ZS2058 is not less than 1 × 108CFU/g or 1 × 108CFU/mL。
In one embodiment of the invention, the ingredient of the inhibitor also includes oligosaccharide.
In one embodiment of the invention, the oligosaccharide is xylo-oligosaccharide.
In one embodiment of the invention, the content of the oligosaccharide is not less than 1%.
In one embodiment of the invention, the ingredient of the inhibitor also includes carrier.
In one embodiment of the invention, the carrier is pharmaceutically acceptable carrier.
In one embodiment of the invention, the carrier is pharmaceutically acceptable filler, wetting agent, disintegration
It is one or more in agent, adhesive, lubricant or corrigent.
The present invention provides a kind of application of the above-mentioned salmonella inhibitor in terms of inhibiting, preventing salmonella.
The present invention provides a kind of application of the above-mentioned salmonella inhibitor in terms of preparing drug, food, health products.
Advantageous effect：
(1) the lactobacillus plantarum ZS2058 that inhibitor of the present invention uses can make the survival rate after mouse infection salmonella from
33.3% is increased to 53.3%, and xylo-oligosaccharide can enhance prevention effects of the lactobacillus plantarum ZS2058 to salmonella infection,
Survival rate is set to be increased to 66.7%, xylo-oligosaccharide makes the function and effect of lactobacillus plantarum ZS2058 improve, and xylo-oligosaccharide makes plant
Object lactobacillus improves 67% ((66.7%-53.3%)/(53.3%-33.3%) * to the preventive effect of salmonella infection
100%=67%)；
(2) inhibitor of the present invention can avoid killing commensal gut flora largely beneficial to human body, occur into enteron aisle work(
The side effects unfavorable to human body such as energy disorder；
(3) inhibitor of the present invention can avoid salmonella from generating resistance, cause disruption of ecological balance；
(4) inhibitor of the present invention has inhibition good, the advantage of no hysteresis quality；
(5) inhibitor of the present invention can be good at reducing the infection rate of salmonella, and the infection rate of salmonella is reduced
60% or so.
Description of the drawings
Inhibiting effect of Fig. 1 differences lactobacillus plantarum to salmonella infection；
Wherein, control is PBS gavages 10 days, after without salmonella infection；Model is PBS gavages 10 days, by
Salmonella infection；M3 groups are lactobacillus plantarum M3 gavages 10 days, by salmonella infection；M6 groups are that lactobacillus plantarum M6 is filled
Stomach 10 days, by salmonella infection；S2 groups are lactobacillus plantarum S2 gavages 10 days, by salmonella infection；T groups are plant
Lactobacillus T gavages 10 days, by salmonella infection；ZS2058 groups are lactobacillus plantarum ZS2058 gavages 10 days, by sramana
Salmonella infects；LGG groups are Lactobacillus rhamnosus GG gavages 10 days, by salmonella infection；
Fig. 2 is the influence that glucose (Glucose) grows lactobacillus plantarum ZS2058；
Fig. 3 is the influence that oligofructose (FOS) grows lactobacillus plantarum ZS2058；
Fig. 4 is the influence that lactulose (Lactulose) grows lactobacillus plantarum ZS2058；
Fig. 5 is the influence that D- cellobioses (D-lactulose) grow lactobacillus plantarum ZS2058；
Fig. 6 is the influence that isomaltose (IMO) grows lactobacillus plantarum ZS2058；
Fig. 7 is the influence that Oligomeric manna sugar (MOS) grows lactobacillus plantarum ZS2058；
Fig. 8 is the influence that inulin (Inulin) grows lactobacillus plantarum ZS2058；
Fig. 9 is the influence that xylo-oligosaccharide (XOS) grows lactobacillus plantarum ZS2058；
Figure 10 is the influence that oligosaccharide grows salmonella typhimurium SL1344；
Wherein, Glucose is in MRS-Glucose is added in culture medium, is control group；FOS is in MRS-Add in culture medium
Enter oligofructose；Lactulose is in MRS-Lactulose is added in culture medium；D-cellobiose is in MRS-Add in culture medium
Enter D- cellobioses；IMO is in MRS-Isomaltose is added in culture medium；MOS is in MRS-Oligomeric sweet dew is added in culture medium
Sugar；Inulin is in MRS-Inulin is added in culture medium；XOS is in MRS-Xylo-oligosaccharide is added in culture medium；
Figure 11 is the inhibiting effect that xylo-oligosaccharide promotes lactobacillus plantarum ZS2058 to salmonella infection；
Wherein, Control groups are feeding normal diet, and PBS gavages do not infect salmonella；Model groups are feeding
Normal diet, PBS gavages infect salmonella；ZS2058 groups are feeding normal diet, and ZS2058 gavages infect salmonella；
XOS+ZS2058 groups are the feed that feeding contains 1% xylo-oligosaccharide, and ZS2058 gavages infect salmonella.
Specific implementation mode
Lactobacillus plantarum (Lactobacillus plantarum) ZS2058 of the present invention is April 10 in 2006
It is preserved in China typical culture collection center preservation day, deposit number is CCTCC No.M206033, and preservation address is Wuhan
City Wuchang road gal mountain.
Culture medium of the present invention is as follows：
MRS fluid nutrient mediums (per 1L)：Tryptone 10g, beef extract 10g, yeast powder 5g, glucose 20g, citric acid
Hydrogen diammonium 2g, anhydrous sodium acetate 5g, dipotassium hydrogen phosphate 2g, epsom salt 0.5g, manganese sulfate monohydrate 0.25g, Tween 80 1mL,
1000mL is added water to, pH is adjusted to 6.2-6.4,115 DEG C, 20min moist heat sterilizations.
MRS-Culture medium：Glucose is subtracted on the basis of MRS culture mediums, is purchased from Qingdao Hai Bo Bioisystech Co., Ltd
It buys.
mMRS-Culture medium：In MRS-The oligosaccharide of addition 2% on the basis of culture medium.
MRS solid mediums (per L)：Agar powder 15g/L is added in fluid nutrient medium.
LB culture mediums (per L)：Yeast powder 5.0g, tryptone 10.0g, sodium chloride 5.0g.Add water 1L, 121 DEG C of 15min wet
Heat sterilization.
Actication of culture method of the present invention is：
With oese from protect tube in a small amount of bacterium solution of picking, lactic acid bacteria (lactobacillus plantarum M3, lactobacillus plantarum M6, plant
Lactobacillus S2, lactobacillus plantarum T, lactobacillus plantarum ZS2058, lactobacillus plantarum ST-III, Lactobacillus rhamnosus GG) it is solid in MRS
It crosses in body tablet, salmonella typhimurium SL1344 crosses in LB solid plates.It is placed in 37 DEG C of constant incubators and cultivates,
Until growing single bacterium colony.
Spawn incubation method of the present invention is：
It is dropped down onto in MRS fluid nutrient mediums with the lactic acid bacteria single bacterium on oese picking MRS solid mediums, 37 DEG C stand training
Support 14-18h.Lactic acid bacteria and salmonella are transferred to 1% inoculum concentration in liquid MRS culture mediums, 37 DEG C of stationary culture 14-18h.
Activation every time is all inoculated with 1% inoculum concentration, 37 degrees Celsius of culture 14-18h.
Embodiment 1：Influence of the different lactobacillus plantarums to salmonella infection
Method is as follows：
Lactobacillus plantarum M3, lactobacillus plantarum M6, lactobacillus plantarum S2, lactobacillus plantarum T, lactobacillus plantarum ZS2058,
Lactobacillus rhamnosus GG is resuspended with PBS to 1 × 109CFU/mL.0.1mL bacteria suspensions are taken to carry out gavage to every group of mouse respectively, even
It is ten days continuous.Salmonella typhimurium SL1344 is resuspended with PBS to 1 × 10 afterwards7CFU/mL takes 0.1mL senses in a manner of gavage
Contaminate mouse.
The results are shown in Figure 1：15 days after infection, each group mouse survival rate is respectively：Control group 100%, model group
46.7%, lactobacillus plantarum M3 group 66.6%%, lactobacillus plantarum M6 groups 53.3%, lactobacillus plantarum S2 groups 66.6%, plant
Lactobacillus T groups 46.7%, lactobacillus plantarum ZS2058 groups 80.0%, Lactobacillus rhamnosus GG groups 75.0%.
It follows that although lactobacillus plantarum all may be with the potentiality of antagonism salmonella, they are dynamic in model
Function and effect in object are different.The function and effect of lactobacillus plantarum T, M6 are smaller, are shown when observing terminal, lactobacillus plantarum
T is to salmonella infection without prevention effect；Lactobacillus plantarum M3, S2 and ZS2058 effect is preferable, especially lactobacillus plantarum
ZS2058 has good prevention effect to salmonella infection.
Embodiment 2：The influence that different oligosaccharide grow lactobacillus plantarum ZS2058
Method is as follows：
(1) preparation of lactobacillus plantarum ZS2058, ST-III, LGG
After lactobacillus plantarum ZS2058, ST-III, LGG passage, centrifuges after 37 DEG C of culture 18h, washed one time with PBS, and
Use MRS-Culture medium is resuspended to 1.0 × 109CFU/ml。
(2) lactobacillus plantarum ZS2058 is inoculated with
Above-mentioned bacterium solution is drawn 0.1ml, and in 5ml to contain different oligosaccharide (xylo-oligosaccharide XOS, oligofructose FOS, oligomeric sweet
Reveal sugar MOS, inulin Inulin, oligoisomaltose IMO, lactulose Lactulose, D- cellobiose D-cellobiose)
In culture medium.
(3) growth curve measures
With spectrophotometer, the OD600 values for measuring different cultures every 2 hours.
As a result as shown in figs. 2-9：The influence that different oligosaccharide grow lactobacillus plantarum ZS2058 is different.FOS、
Lactulose, D-cellobiose are similar to glucose to lactobacillus plantarum ZS2058 growths, in 36h, OD600 about 1.10；
According to the OD600 of 36h, other sugar are IMO to the facilitation of lactobacillus plantarum ZS2058 growths>MOS>Inulin>XOS.
It follows that the influence that different oligosaccharide grow lactobacillus plantarum ZS2058 is different.
Embodiment 3：Influence of the different oligosaccharide to Salmonella growth
(1) preparation of salmonella typhimurium SL1344
After salmonella typhimurium SL1344 passages, is centrifuged after 37 DEG C of culture 18h, washed one time with PBS, MRS is used in combination-Training
Foster base weight is hanged to 1.0 × 109CFU/ml。
(2) salmonella typhimurium SL1344 is inoculated with
Above-mentioned bacterium solution is drawn into 0.1ml in the culture medium that 5ml contains different oligosaccharide.
(3) growth curve measures
With spectrophotometer, the OD600 values for measuring different cultures every 2 hours.
The results are shown in Figure 10：The influence that different oligosaccharide grow salmonella typhimurium SL1344 is different.According to 36h
When OD600, inulin Inulin promotes the growth of salmonella typhimurium SL1344；Other oligosaccharide do not promote even to inhibit
The growth of salmonella typhimurium SL1344；Xylo-oligosaccharide XOS then obviously inhibits the growth of salmonella.
It follows that the influence that different oligosaccharide grow salmonella typhimurium SL1344 is different, oligosaccharide inulin
Inulin, oligoisomaltose IMO, oligofructose FOS, Oligomeric manna sugar MOS, lactulose Lactulose and D- cellobiose
D-cellobiose cannot inhibit salmonella typhimurium SL1344 to grow, and oligosaccharide xylo-oligosaccharide XOS can inhibit mouse typhus husky
The SL1344 growths of door Salmonella.
Embodiment 4：Xylo-oligosaccharide promotes inhibiting effect of the lactobacillus plantarum ZS2058 to salmonella infection
(1) preparation of lactobacillus plantarum ZS2058
After lactobacillus plantarum ZS2058 passages, centrifuges, washed three times with cold PBS, and be resuspended after 37 DEG C of culture 18h.
(2) preparation of Salmonella cultures
The culture medium of salmonella typhimurium SL1344 is LB culture mediums, and salmonella is with the inoculation of 2% (2mL/100mL)
After amount carries out activation culture in LB culture mediums, 37 DEG C of 225rpm shake cultures 12h.
(3) preparation of oligosaccharide feed
Mouse irradiated feed is broken into powder, adds xylo-oligosaccharide (XOS), oligofructose that mass fraction is 1% respectively
(FOS), Oligomeric manna sugar (MOS), inulin (Inulin), glucose (Glucose, control), forming.
As a result as shown in figure 11：After salmonella infection 18 days, normal mouse survival rate of organizing is 100%；Model group mouse
Survival rate is 33.3%；Lactobacillus plantarum ZS2058 processing group mouse survival rates are 53.3%；Xylo-oligosaccharide and lactobacillus plantarum
ZS2058 processing group mouse survival rates are 66.7%；Oligofructose and lactobacillus plantarum ZS2058 processing group mouse survival rates are
46.7%；Oligomeric manna sugar and lactobacillus plantarum ZS2058 processing group mouse survival rates are 26.7%；Inulin and lactobacillus plantarum
ZS2058 processing group mouse survival rates are 40.0%；Glucose and lactobacillus plantarum ZS2058 processing group mouse survival rates are
40.0%.Illustrate the inhibiting effect having and only xylo-oligosaccharide can enhance lactobacillus plantarum ZS2058 to salmonella infection.
From embodiment 2-4：Although the facilitation that xylo-oligosaccharide grows lactobacillus plantarum ZS2058 is weaker,
Xylo-oligosaccharide can enhance inhibiting effect of the lactobacillus plantarum ZS2058 to salmonella infection, and the two acts synergistically on salmonella
Effect be much better than the effect of lactobacillus plantarum ZS2058 independent roles and salmonella.
Although the present invention has been described by way of example and in terms of the preferred embodiments, it is not limited to the present invention, any to be familiar with this skill
The people of art can do various change and modification, therefore the protection model of the present invention without departing from the spirit and scope of the present invention
Enclosing be subject to what claims were defined.
Claims (10)
1. a kind of salmonella inhibitor, which is characterized in that the ingredient of the inhibitor includes lactobacillus plantarum and/or its metabolism
Object；The lactobacillus plantarum is lactobacillus plantarum (Lactobacillus plantarum) ZS2058；The lactobacillus plantarum
(Lactobacillus plantarum) ZS2058 is preserved in China typical culture collection center on April 10th, 2006
Preservation, deposit number are CCTCC No.M206033, and preservation address is wuchang, wuhan road gal mountain.
2. a kind of salmonella inhibitor as described in claim 1, which is characterized in that the lactobacillus plantarum
The content of (Lactobacillus plantarum) ZS2058 is not less than 1 × 108CFU/g or 1 × 108CFU/mL。
3. a kind of salmonella inhibitor as claimed in claim 1 or 2, which is characterized in that the ingredient of the inhibitor also wraps
Containing oligosaccharide.
4. a kind of salmonella inhibitor as claimed in claim 3, which is characterized in that the oligosaccharide is xylo-oligosaccharide.
5. a kind of salmonella inhibitor as described in claim 3 or 4, which is characterized in that the content of the oligosaccharide is not low
In 1%.
6. a kind of salmonella inhibitor according to any one of claims 1 to 5, which is characterized in that the ingredient of the inhibitor is also
Including carrier.
7. a kind of salmonella inhibitor as claimed in claim 6, which is characterized in that the carrier is pharmaceutically acceptable
Carrier.
8. a kind of salmonella inhibitor as claimed in claims 6 or 7, which is characterized in that the carrier is that can pharmaceutically connect
It is one or more in filler, wetting agent, disintegrant, adhesive, lubricant or the corrigent received.
9. a kind of application of any salmonella inhibitor of claim 1-8 in terms of inhibiting, preventing salmonella.
10. a kind of any salmonella inhibitor the answering in terms of preparing drug, food, health products of claim 1-8
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810400614.7A CN108478604A (en) | 2018-04-28 | 2018-04-28 | A kind of salmonella inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810400614.7A CN108478604A (en) | 2018-04-28 | 2018-04-28 | A kind of salmonella inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108478604A true CN108478604A (en) | 2018-09-04 |
Family
ID=63314456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810400614.7A Pending CN108478604A (en) | 2018-04-28 | 2018-04-28 | A kind of salmonella inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108478604A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110859860A (en) * | 2019-11-20 | 2020-03-06 | 江南大学 | Product for preventing and/or treating salmonella infection |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1195095A2 (en) * | 2000-10-05 | 2002-04-10 | St. Ivel Limited | Food products with antimicrobial lactic acid bacteria |
| CN105106246A (en) * | 2015-08-20 | 2015-12-02 | 江南大学 | Lactobacillus plantarum ZS2058 and application thereof |
| CN105779350A (en) * | 2016-04-11 | 2016-07-20 | 北京科拓恒通生物技术开发有限公司 | Lactobacillus plantarum resistant to enteritis salmonella infection and application thereof |
-
2018
- 2018-04-28 CN CN201810400614.7A patent/CN108478604A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1195095A2 (en) * | 2000-10-05 | 2002-04-10 | St. Ivel Limited | Food products with antimicrobial lactic acid bacteria |
| CN105106246A (en) * | 2015-08-20 | 2015-12-02 | 江南大学 | Lactobacillus plantarum ZS2058 and application thereof |
| CN105779350A (en) * | 2016-04-11 | 2016-07-20 | 北京科拓恒通生物技术开发有限公司 | Lactobacillus plantarum resistant to enteritis salmonella infection and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| LAURA J.FOOKS等: "In vitro investigations of the effect of probiotics and prebiotics on selected human intestinal pathogens", 《FEMS MICROBIOLOGY ECOLOGY》 * |
| 安浩: "复合益生菌对小鼠和家兔生长性能以及肠道调理作用的影响", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
| 尹小良等: "植物乳杆菌ZR09体外抑菌试验", 《农业与技术》 * |
| 徐海燕等: "低聚木糖对益生菌及人肠道菌群的影响", 《药学研究》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110859860A (en) * | 2019-11-20 | 2020-03-06 | 江南大学 | Product for preventing and/or treating salmonella infection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104830731B (en) | One strain has plant lactobacillus AB-1 and the application thereof of broad-spectrum antibacterial characteristic | |
| ES2534750T3 (en) | Lactobacillus pentosus that produces and uses bacteriocins in food and pharmaceutical compositions | |
| CN105779350B (en) | A kind of lactobacillus plantarum and application thereof of anti-Bacterium enteritidis infection | |
| CN109234182B (en) | Lactobacillus plantarum ZJUFT34 and application thereof | |
| JP2007518693A (en) | Stable liquid probiotic composition, its preparation and application | |
| CN104611251B (en) | One plant has the active lactic acid bacteria of broad-spectrum antibacterial and its application | |
| WO2021177526A1 (en) | Breast milk-derived lactobacillus reuteri lm1071 strain having excellent safety and intestinal adhesiveness, and composition comprising strain or cultured product thereof | |
| CN107858302B (en) | Bacillus subtilis 7K and application thereof | |
| Russell et al. | Potential effect of cattle diets on the transmission of pathogenic Escherichia coli to humans | |
| Collins et al. | Survival of Arcobacter butzleri and Campylobacter jejuni after irradiation treatment in vacuum-packaged ground pork | |
| CN115354002B (en) | Bacillus coagulans BC07, application thereof, and bacteriostat, medicine, food and bacteriostasis method thereof | |
| CN107177522A (en) | One plant height activity forage plant lactobacillus and its cultural method and application | |
| US20040191233A1 (en) | Bifidobacteria and siderophores produced thereby and methods of use | |
| CN113040390A (en) | Probiotic and salt-tolerant Lactobacillus johnsonii strain and application thereof in prevention and treatment of pathogenic bacteria in livestock and poultry aquaculture | |
| CN109121394A (en) | Purposes of the phycocyanin that is purifying or being present in cyanobacteria microalgae or its extract as prebiotics, to enhance survival rate, gastrointestinal tract survival, anti-pathogenic capacity and the holistic health enhancing characteristic of probiotic bacterial cultures and product | |
| CN116790409A (en) | Lactobacillus reuteri and preparation and application of microecological preparation thereof | |
| CN100558883C (en) | New bacterial strain with genus bifidobacterium of the ability that produces glutamine | |
| CN108478604A (en) | A kind of salmonella inhibitor | |
| CN110859860B (en) | Product for preventing and/or treating salmonella infection | |
| TW201242517A (en) | Novel pediococcus pentosaceus, composition containing the same, and use thereof | |
| Cutter et al. | Major microbiological hazards associated with packaged fresh and processed meat and poultry | |
| CN108157978A (en) | A kind of peptide composition of adjusting intestinal flora containing burdock polysaccharide and application | |
| CN112450355A (en) | Application and application of antibacterial peptide Cm-CATH2 in inhibition of vibrio parahaemolyticus in marine products | |
| CN105725215A (en) | Lactobacillus oral solution and preparation method thereof | |
| Verruck et al. | Survival of Bifidobacterium ssp. during gastrointestinal passage and their mechanism of action for pathogenic bacteria inhibition in the gut: a concise review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180904 |
|
| RJ01 | Rejection of invention patent application after publication |